Burlibact T 1000mg/125mg Injection
By Burlibact T
Rx
1 Injection in a Vial

Composition
Ceftriaxone(1000mg) + Tazobactum(125mg)

Manufacturer - Unibiotech Formulations
plot no. 55, sector 82, jlpl industrial area, sahibzada ajit singh nagar, punjab 160055

Expires on or after
September, 2025

liver
When using Burlibact T 1000mg/125mg Injection, it's important to be cautious if you have severe liver disease. In such cases, the dosage of Burlibact T 1000mg/125mg Injection may need to be adjusted. It's crucial to consult your doctor before starting treatment with Burlibact T 1000mg/125mg Injection if you have severe liver disease. However, if you have mild to moderate liver disease, dose adjustment of Burlibact T 1000mg/125mg Injection is not typically recommended. Always follow your doctor's guidance and advice regarding the use of Burlibact T 1000mg/125mg Injection in relation to your liver health.

kidney
Limited data exists on the use of Burlibact T 1000mg/125mg Injection in people with kidney issues. It's recommended to seek advice from your doctor.

alcohol
When taking Burlibact T 1000mg/125mg Injection, it is safe to consume alcohol as it does not lead to any harmful effects.

driving
Burlibact T 1000mg/125mg Injection may reduce alertness and cause drowsiness or dizziness. It is advised not to drive if experiencing these symptoms.

pregnancy
Burlibact T 1000mg/125mg Injection is generally safe during pregnancy. Animal studies show minimal harm to the baby, but human studies are limited.

breastfeeding
Burlibact T 1000mg/125mg Injection should be used cautiously while breastfeeding. It is advised to temporarily stop breastfeeding until the mother's treatment is finished and the medicine is cleared from her system.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | ANTI INFECTIVES |
Action Class | - |
₹160
Inclusive of all taxes
Content verified by

Dr. Preeti Kumar
MBBS, DGO - Obstetrics and Gynaecology, DNB - Obstetrics and Gynaecology
Last update on 01-Oct-2024